• The main features of pregnancy and delivery management in patients with idiopathic thrombocytopenic purpura 
To content

The main features of pregnancy and delivery management in patients with idiopathic thrombocytopenic purpura 

HEALTH OF WOMAN.2015.7(103):83–87 
 

The main features of pregnancy and delivery management in patients with idiopathic thrombocytopenic purpura 
 

Golyanovskyy O. V., Zhuravlova L. A., Shutka A. B., Galich I. D., Rubinshtein A. M.

National Medical Academy of Postgraduate Education P. L. Shupyk, Kiev

Kyiv regional center of health protection of mother and child 
 

The article presents modern data on the etiology, pathogenesis and diagnostics of the Verlgofa disease, peculiarities of pregnancy, delivery and the postpartum period management in patients with this pathology. A clinical case of successful complex therapy of MOH in the early postpartum period on the background of idiopathic thrombocytopenic purpura has been described. 
 

Key words: Verlgofa disease, idiopathic thrombocytopenic purpura, pregnancy, РРН. 
 

REFERENCES

1. Аллергология и иммунология: национальное руководство. Под. ред. Хаитова РМ, Ильиной НИ. М, ГЭОТАР-Медиа, 2009.

2. Алтыбаев УА. 1984. Выявление, методы лечения, диспансеризация и реабилитация больных тромбоцитопенической пурпурой. Автореф. дис. д. мед. наук. М.

3. Андреева НЕ, Идельсон ЛИ. 1978. Тромбоцитопенические геморрагические состояния. М.

4. Баркаган ЗС. 1988. Геморрагические заболевания и синдромы. М.

5. Климанский ВА. 1984. Клин. мед. 62;1:140–146.

6. Корнеева ЕА. 1994. Физиология человека. 20;2:199–201.

7. Кульберг АЯ. 1996. Регуляция иммунного ответа. М:57–64.

8. Соколова МЮ. 2002. Акуш. и гин. 6:65-68.

9. Цепа ЛС. 1986. Тромбоцитопеническая пурпура (болезнь Верльгофа). Патогенез, клиника, лечение. Дис. д. мед. наук. М.

10. Шехтман ММ, Бурдули ГМ. 1997. Болезни органов пищеварения и крови у беременных. М:218–307.

11. Шехтман ММ. 1999. Руководство по экстрагенитальной патологии. М:435–514.

12. Arnold DM, Kelton JG. 2007. Current options for the treatment of idiopathic thrombocytopenic purpura. Semin Hematol. 44:S12–S23. http://dx.doi.org/10.1053/j.seminhematol.2007.11.003; PMid:18096468

13. Andersson P-O, Olsson A, Wadenvik H. 2002. Reduced transforming growth factor-b1 production by mononuclear cells from patients with active chronic idiopathic thrombocytopenic purpura. Br. J. Haematol. 116:862–67http://dx.doi.org/10.1046/j.0007-1048.2002.03345.x

14. Chang M, Nakagawa PA, Williams SA et al. 2003. Immune thrombocytopenic purpura (ITP) plasma and purified ITP monoclonal autoantibodies inhibit megakaryocytopoiesis in vitro. Blood 102:887–95. http://dx.doi.org/10.1182/blood-2002-05-1475; PMid:12676790

15. Cines DB, Blanchette VS. 2002. Immune thrombocytopenic purpura. N. Engl. J.Med. 346:995–1008. http://dx.doi.org/10.1056/NEJMra010501; PMid:11919310

16. Cooper N, Bussel J. The pathogenesis of immune thrombocytopaenic purpura. Br J Haematol 2006;133:364–374. http://dx.doi.org/10.1111/j.1365-2141.2006.06024.x; PMid:16643442

17. Emmons RVB, Reid DM, Cohen RL et al. 1996. Human thrombopoietin levels are high when thrombocytopenia is due to megakaryocyte deficiency and low when due to increased destruction. Blood 87:4068–71. PMid:8639762

18. George JN, El-Harake MA, Aster RH. 1995. Thrombocytopenia due to enhanced platelet destruction by immunologic mechanisms. In Williams Hematology, ed. E Beutler, M.A. Lichtman, B.S. Coller, T.J. Kipps. New York: McGraw-Hill:1315–55.

19. Heyns AP, Badenhorst PN, Lotter MG et al. 1986. Platelet turnover and kinetics in immune thrombocytopenic purpura: results with autologous 111-In-labeled and homologous 51-Cr-labeled platelets differ. Blood 67:86–92.

20. Kuwana K, Kaburaki J, Ikeda Y. 1998. Autoreactive T cells to platelet GPIIb-IIIa in immune thrombocytopenic purpura. Role in production of antiplatelet autoantibody. J. Clin. Invest. 102:1393–402. http://dx.doi.org/10.1172/JCI4238; PMid:9769332 PMCid:PMC508987

21. Kuwana M, Okazaki Y, Kaburaki J et al. 2003. Spleen is the primary site for activation of plateletreactive T and B cells in patients with immune thrombocytopenic purpura. J. Immunol. 168:3675–82. http://dx.doi.org/10.4049/jimmunol.168.7.3675

22. McMillan R, Yelenosky RJ, Longmire RL. 1976. Antiplatelet antibody production by the spleen and bone marrow in immune thrombocytopenic purpura. In Immunoaspects of the Spleen, ed. J.R. Battisto, J.W. Streinlein. Amsterdam: North Holland Biomed:227–37

23. McMillan R. 2000. Autoantibodies and autoantigens in chronic immune thrombocytopenic purpura. Semin. Hematol. 37:239–48. http://dx.doi.org/10.1016/S0037-1963(00)90111-2http://dx.doi.org/10.1016/S0037-1963(00)90102-1

24. McMillan R, Imbach P. 2003. Immune thrombocytopenic purpura. In Thrombosis and Hemorrhage, ed. J Loscalzo, A.I. Schafer, pp. 476–95. Philadelphia: Lippincott Williams & WilkinsMcMillan R., Wang L., Tomer A et al. 2004. Suppression of in vitro megakaryocyte production by antiplatelet autoantibodies from adult chronic ITP patients. Blood 103:1364–69

25. Mouzaki A, Theodoropoulou M, Gianakopoulos I et al. 2002. Expression patterns of Th1 and Th2 cytokine genes in childhood idiopathic thrombocytopenic purpura (ITP) at presentation and their modulation by intravenous immunoglobulin G (IVIg) treatment: their role in prognosis. Blood 100:1774–79. PMid:12176899

26. Olsson B, Andersson P, Jernas M et al. 2003. T-cell-mediated cytotoxicity toward platelets in chronic idiopathic thrombocytopenic purpura. Nat. Med. 9:1123–24. http://dx.doi.org/10.1038/nm921; PMid:12937414

27. Semple JW, Milev Y, Cosgrave D et al. 1996. Differences in serum cytokine levels in acute and chronic autoimmune thrombocytopenic purpura: relationship to platelet phenotype and antiplatelet T-cell reactivity. Blood 87:4245–54. PMid:8639783

28. Stoll D, Cines DB, Aster RH et al. 1985. Platelet kinetics in patients with idiopathic thrombocytopenic purpura and moderate thrombocytopenia. Blood 65:584–88. PMid:4038614